Login / Signup

The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.

Anita J BroganSandra E TalbirdAshley E DavisElizabeth M LaPrincy N Kumar
Published in: PharmacoEconomics (2021)
Ibalizumab may represent a cost-effective and affordable option to improve health outcomes for individuals with MDR HIV-1 infection.
Keyphrases
  • multidrug resistant
  • antiretroviral therapy
  • drug resistant
  • gram negative
  • acinetobacter baumannii
  • klebsiella pneumoniae
  • pseudomonas aeruginosa